WO1995013093A1 - Traitement d'un patient avant une transplantation - Google Patents

Traitement d'un patient avant une transplantation Download PDF

Info

Publication number
WO1995013093A1
WO1995013093A1 PCT/GB1994/002470 GB9402470W WO9513093A1 WO 1995013093 A1 WO1995013093 A1 WO 1995013093A1 GB 9402470 W GB9402470 W GB 9402470W WO 9513093 A1 WO9513093 A1 WO 9513093A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cells
treatment
stem cells
transplantation
Prior art date
Application number
PCT/GB1994/002470
Other languages
English (en)
Inventor
Johan Herman Frederik Falkenburg
Original Assignee
Leiden University
Cantab Pharmaceuticals Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiden University, Cantab Pharmaceuticals Research Limited filed Critical Leiden University
Priority to AU81132/94A priority Critical patent/AU8113294A/en
Publication of WO1995013093A1 publication Critical patent/WO1995013093A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • anti-CD45 antibody is not restricted in its action to T-cells: for instance, it can also act on NK cells.
  • Anti-CD45 can act on lymphocytes and monocytes and is likely to be able to eliminate them. It can be useful to apply in this way a treatment with a broad spectrum of cell killing, and can help to minimise graft rejection.
  • the two cell lines YTH24.5 and YTH54.12 were originally produced from a cell fusion between spleen cells from a rat immunised with human T cells and the rat myeloma cell line Y3/Agl.2.3 (deposited under accession number C.N.C.M. 1-078; see US patent 4350683).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Selon l'invention, on utilise un anticorps dirigé contre un antigène trouvé sur des cellules souches hématopoïétiques, dans le traitement de patients avant une transplantation de cellules souches hématopoïétiques. Dans la thérapie d'une tumeur, un antigène peut être présent à la fois sur les cellules souches hématoïétiques et sur les cellules tumorales. On préfère l'anticorps anti-CD45. Un anticorps non humain est rapidement éliminé du flux sanguin avant une transplantation, évitant ainsi une réaction avec des cellules souches transplantées. On peut vraisemblablement combiner ce traitement avec d'autres traitements destinés à combattre les tumeurs, bien qu'on l'utilise également dans le traitement de maladies non malignes.
PCT/GB1994/002470 1993-11-10 1994-11-10 Traitement d'un patient avant une transplantation WO1995013093A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU81132/94A AU8113294A (en) 1993-11-10 1994-11-10 Treatment of a patient prior to transplantation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323199A GB9323199D0 (en) 1993-11-10 1993-11-10 Leukaemia treatment
GB9323199.1 1993-11-10

Publications (1)

Publication Number Publication Date
WO1995013093A1 true WO1995013093A1 (fr) 1995-05-18

Family

ID=10744958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/002470 WO1995013093A1 (fr) 1993-11-10 1994-11-10 Traitement d'un patient avant une transplantation

Country Status (3)

Country Link
AU (1) AU8113294A (fr)
GB (1) GB9323199D0 (fr)
WO (1) WO1995013093A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164502A1 (fr) 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions et procédés s'appliquant au conditionnement non myéloablatif
RU2645069C2 (ru) * 2010-08-18 2018-02-15 Авм Байотекнолоджи, Ллс Композиции и способы для ингибирования связывания стволовых клеток и клеток-предшественников с лимфоидной тканью и для регенерации зародышевых центров в лимфатических тканях
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
US10434185B2 (en) 2017-01-20 2019-10-08 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US10624973B2 (en) 2016-06-17 2020-04-21 Magenta Therapeutics, Inc. Methods for the depletion of cells
EP3255061B1 (fr) 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Immunodéplétion sélective de niche de cellules souches endogènes pour greffe
US11219628B2 (en) 2017-04-01 2022-01-11 Avm Biotechnology, Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
WO2022063853A1 (fr) 2020-09-25 2022-03-31 Adc Therapeutics Sa Conjugués pyrrolobenzodiazépine-anticorps et leurs utilisations
WO2022064191A1 (fr) 2020-09-25 2022-03-31 Ucl Business Ltd Anticorps anti-cd45 et agents thérapeutiques associés
US11446314B2 (en) 2018-10-03 2022-09-20 Avm Biotechnology, Llc Immunoablative therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
WO1993007900A1 (fr) * 1991-10-18 1993-04-29 Cantab Pharmaceuticals Research Limited Perfusion in vitro de greffes de reins avec des anticorps
US5273738A (en) * 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US5273738A (en) * 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
WO1993007900A1 (fr) * 1991-10-18 1993-04-29 Cantab Pharmaceuticals Research Limited Perfusion in vitro de greffes de reins avec des anticorps

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
C. BINDON ET AL.: "Synergistic complement lysis by monoclonal antibodies to the human leukocyte common antigen requires both the classical and alternative pathways.", MOLECULAR IMMUNOLOGY, vol. 24, no. 6, 1987, pages 587 - 594 *
C. BINDON ET AL.: "Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen.", TRANSPLANTATION, vol. 40, no. 5, 1985, BALTIMORE MD, USA, pages 538 - 544 *
F. UCKUN ET AL.: "Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging.", BLOOD, vol. 76, no. 9, 1 November 1990 (1990-11-01), NEW YORK NY, USA, pages 1723 - 1733 *
G. HALE ET AL.: "Therapeutic potential of rat monoclonal antibodies: Isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes.", THE JOURNAL OF IMMUNOLOGY, vol. 134, no. 5, May 1985 (1985-05-01), BALTIMORE MD, USA, pages 3056 - 3061 *
M. DYER ET AL.: "Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonal antibodies.", LEUKEMIA AND LYMPHOMA, vol. 2, no. 3-4, 1990, CHUR, SWITZERLAND, pages 179 - 193 *
P. DE FABRITIIS ET AL.: "Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement.", BLOOD, vol. 65, no. 5, May 1985 (1985-05-01), NEW YORK NY, USA, pages 1064 - 1070 *
Y. BREWER ET AL.: "Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection.", THE LANCET, vol. 2, no. 8669, 21 October 1989 (1989-10-21), LONDON, GB, pages 935 - 937 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255061B1 (fr) 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Immunodéplétion sélective de niche de cellules souches endogènes pour greffe
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
RU2645069C2 (ru) * 2010-08-18 2018-02-15 Авм Байотекнолоджи, Ллс Композиции и способы для ингибирования связывания стволовых клеток и клеток-предшественников с лимфоидной тканью и для регенерации зародышевых центров в лимфатических тканях
US10570207B2 (en) 2015-04-06 2020-02-25 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
US10280225B2 (en) 2015-04-06 2019-05-07 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
WO2016164502A1 (fr) 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions et procédés s'appliquant au conditionnement non myéloablatif
US10906980B2 (en) 2015-04-06 2021-02-02 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
US10624973B2 (en) 2016-06-17 2020-04-21 Magenta Therapeutics, Inc. Methods for the depletion of cells
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
US10434185B2 (en) 2017-01-20 2019-10-08 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US10576161B2 (en) 2017-01-20 2020-03-03 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US11219628B2 (en) 2017-04-01 2022-01-11 Avm Biotechnology, Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
US11446314B2 (en) 2018-10-03 2022-09-20 Avm Biotechnology, Llc Immunoablative therapies
WO2022063853A1 (fr) 2020-09-25 2022-03-31 Adc Therapeutics Sa Conjugués pyrrolobenzodiazépine-anticorps et leurs utilisations
WO2022064191A1 (fr) 2020-09-25 2022-03-31 Ucl Business Ltd Anticorps anti-cd45 et agents thérapeutiques associés

Also Published As

Publication number Publication date
GB9323199D0 (en) 1994-01-05
AU8113294A (en) 1995-05-29

Similar Documents

Publication Publication Date Title
Jin et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells
Sharabi et al. Specific tolerance induction across a xenogeneic barrier: production of mixed rat/mouse lymphohematopoietic chimeras using a nonlethal preparative regimen.
JP3731892B2 (ja) 造血幹細胞の末梢化
Seon et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Cobbold et al. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance
US7709000B2 (en) Antibody recognizing a small subset of human hematopoietic cells
Anderson et al. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma
Lin et al. Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment
Brett et al. Repopulation of blood lymphocyte sub‐populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH‐1H
CN108137648A (zh) 用于非清髓性预处理的组合物和方法
AU679437B2 (en) Induced tolerance to xenografts
JP2001523645A (ja) 血液学的疾患の処置
US5635156A (en) Non-lethal methods for conditioning a recipient for bone marrow transplantation
Perico et al. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation.
MXPA02001398A (es) Tratamiento de pacientes que tienen linfoma no hodgkins con lesion de medula osea con anticuerpos anti-cd20.
CA2319764A1 (fr) Inhibition d'un trajet de stimulation associee et chimerisme mixte en transplantation
US5514364A (en) Non-lethal methods for conditioning a recipient for bone marrow transplantation
KR20190109440A (ko) 줄기 세포 이식을 위한 비-유전독성 컨디셔닝 레지멘
Iwahashi et al. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model
WO1995013093A1 (fr) Traitement d'un patient avant une transplantation
Heijnen et al. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
EA007467B1 (ru) Применение cd23 антагонистов для лечения опухолевых заболеваний
JP2008507473A (ja) 移植片拒絶におけるｃｄ２０の検出
Sunkara Novel approaches to cancer chemotherapy
Cho et al. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642